Format

Send to

Choose Destination
See comment in PubMed Commons below
Respir Res. 2013 Jul 13;14:73. doi: 10.1186/1465-9921-14-73.

Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.

Author information

1
University of California San Francisco, San Francisco, CA, USA. hal.collard@ucsf.edu

Abstract

BACKGROUND:

Acute exacerbation of idiopathic pulmonary fibrosis has become an important outcome measure in clinical trials. This study aimed to explore the concept of suspected acute exacerbation as an outcome measure.

METHODS:

Three investigators retrospectively reviewed subjects enrolled in the Sildenafil Trial of Exercise Performance in IPF who experienced a respiratory serious adverse event during the course of the study. Events were classified as definite acute exacerbation, suspected acute exacerbation, or other, according to established criteria.

RESULTS:

Thirty-five events were identified. Four were classified as definite acute exacerbation, fourteen as suspected acute exacerbation, and seventeen as other. Definite and suspected acute exacerbations were clinically indistinguishable. Both were most common in the winter and spring months and were associated with a high risk of disease progression and short-term mortality.

CONCLUSIONS:

In this study one half of respiratory serious adverse events were attributed to definite or suspected acute exacerbations. Suspected acute exacerbations are clinically indistinguishable from definite acute exacerbations and represent clinically meaningful events. Clinical trialists should consider capturing both definite and suspected acute exacerbations as outcome measures.

PMID:
23848435
PMCID:
PMC3729659
DOI:
10.1186/1465-9921-14-73
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center